Certara, Inc. (NASDAQ:CERT) Receives Average Rating of “Hold” from Brokerages

Shares of Certara, Inc. (NASDAQ:CERT – Get Free Report) have been assigned a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $8.28.

Several equities analysts have issued reports on the stock. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. Barclays lifted their target price on Certara from $6.50 to $7.50 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th.

Get Certara alerts:

Read Our Latest Research Report on CERT

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Central Pacific Bank Trust Division raised its position in shares of Certara by 8.7% in the 2nd quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock worth $127,000 after acquiring an additional 1,558 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Certara by 12.0% in the second quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock valued at $117,000 after purchasing an additional 1,923 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Certara by 12.1% in the first quarter. The Manufacturers Life Insurance Company now owns 23,289 shares of the company’s stock worth $133,000 after purchasing an additional 2,513 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of Certara by 28.1% during the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock valued at $75,000 after buying an additional 2,871 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Certara by 22.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 24,972 shares of the company’s stock valued at $142,000 after buying an additional 4,618 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Performance

Shares of Certara stock opened at $8.89 on Friday. The firm’s 50-day moving average is $8.01 and its 200 day moving average is $6.65. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -19.76 and a beta of 1.40. Certara has a 1 year low of $4.45 and a 1 year high of $13.88. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55.

Certara (NASDAQ:CERT – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The company’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.07 EPS. Sell-side analysts anticipate that Certara will post 0.22 EPS for the current fiscal year.

Certara Company Profile

(Get Free Report)

Certara (NASDAQ:CERT) provides software and technology-enabled services that support the development, approval and commercialization of medicines. The company specializes in model-informed drug development, using pharmacometrics, simulation, data analysis and regulatory science to help biopharmaceutical companies evaluate drug safety, efficacy, dosing and potential regulatory outcomes.

Its software portfolio includes platforms such as Simcyp, which supports clinical pharmacology and drug-interaction modeling; Phoenix, used for pharmacokinetic and pharmacodynamic analysis; and Pinnacle 21, which helps organizations manage clinical data standards and regulatory submissions.

See Also

• Five stocks we like better than Certara
• Cintas Raises Guidance as a Major Catalyst Moves Closer
• 3 Space Stocks to Watch as SpaceX Reshapes the Launch Market
• Dave’s Success Has Investors Split
• Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.